136 related articles for article (PubMed ID: 28647392)
1. A novel dual inhibitor of microtubule and Bruton's tyrosine kinase inhibits survival of multiple myeloma and osteoclastogenesis.
Pandey MK; Gowda K; Sung SS; Abraham T; Budak-Alpdogan T; Talamo G; Dovat S; Amin S
Exp Hematol; 2017 Sep; 53():31-42. PubMed ID: 28647392
[TBL] [Abstract][Full Text] [Related]
2. Caffeic acid 3,4-dihydroxy-phenethyl ester suppresses receptor activator of NF-κB ligand–induced osteoclastogenesis and prevents ovariectomy-induced bone loss through inhibition of mitogen-activated protein kinase/activator protein 1 and Ca2+–nuclear factor of activated T-cells cytoplasmic 1 signaling pathways.
Wu X; Li Z; Yang Z; Zheng C; Jing J; Chen Y; Ye X; Lian X; Qiu W; Yang F; Tang J; Xiao J; Liu M; Luo J
J Bone Miner Res; 2012 Jun; 27(6):1298-1308. PubMed ID: 22337253
[TBL] [Abstract][Full Text] [Related]
3. Role of Bruton's tyrosine kinase in myeloma cell migration and induction of bone disease.
Bam R; Ling W; Khan S; Pennisi A; Venkateshaiah SU; Li X; van Rhee F; Usmani S; Barlogie B; Shaughnessy J; Epstein J; Yaccoby S
Am J Hematol; 2013 Jun; 88(6):463-71. PubMed ID: 23456977
[TBL] [Abstract][Full Text] [Related]
4. Simvastatin, 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, suppresses osteoclastogenesis induced by receptor activator of nuclear factor-kappaB ligand through modulation of NF-kappaB pathway.
Ahn KS; Sethi G; Chaturvedi MM; Aggarwal BB
Int J Cancer; 2008 Oct; 123(8):1733-40. PubMed ID: 18688862
[TBL] [Abstract][Full Text] [Related]
5. Carvacrol Inhibits Osteoclastogenesis and Negatively Regulates the Survival of Mature Osteoclasts.
Deepak V; Kasonga A; Kruger MC; Coetzee M
Biol Pharm Bull; 2016 Jul; 39(7):1150-8. PubMed ID: 27170515
[TBL] [Abstract][Full Text] [Related]
6. 12-O-tetradecanoylphorbol-13-acetate (TPA) inhibits osteoclastogenesis by suppressing RANKL-induced NF-kappaB activation.
Wang C; Steer JH; Joyce DA; Yip KH; Zheng MH; Xu J
J Bone Miner Res; 2003 Dec; 18(12):2159-68. PubMed ID: 14672351
[TBL] [Abstract][Full Text] [Related]
7. Stattic inhibits RANKL-mediated osteoclastogenesis by suppressing activation of STAT3 and NF-κB pathways.
Li CH; Xu LL; Jian LL; Yu RH; Zhao JX; Sun L; Du GH; Liu XY
Int Immunopharmacol; 2018 May; 58():136-144. PubMed ID: 29587202
[TBL] [Abstract][Full Text] [Related]
8. Maslinic acid suppresses osteoclastogenesis and prevents ovariectomy-induced bone loss by regulating RANKL-mediated NF-κB and MAPK signaling pathways.
Li C; Yang Z; Li Z; Ma Y; Zhang L; Zheng C; Qiu W; Wu X; Wang X; Li H; Tang J; Qian M; Li D; Wang P; Luo J; Liu M
J Bone Miner Res; 2011 Mar; 26(3):644-56. PubMed ID: 20814972
[TBL] [Abstract][Full Text] [Related]
9. Gambogic acid inhibits multiple myeloma mediated osteoclastogenesis through suppression of chemokine receptor CXCR4 signaling pathways.
Pandey MK; Kale VP; Song C; Sung SS; Sharma AK; Talamo G; Dovat S; Amin SG
Exp Hematol; 2014 Oct; 42(10):883-96. PubMed ID: 25034231
[TBL] [Abstract][Full Text] [Related]
10. META060 inhibits osteoclastogenesis and matrix metalloproteinases in vitro and reduces bone and cartilage degradation in a mouse model of rheumatoid arthritis.
Konda VR; Desai A; Darland G; Bland JS; Tripp ML
Arthritis Rheum; 2010 Jun; 62(6):1683-92. PubMed ID: 20201075
[TBL] [Abstract][Full Text] [Related]
11. Ibrutinib inhibits BTK-driven NF-κB p65 activity to overcome bortezomib-resistance in multiple myeloma.
Murray MY; Zaitseva L; Auger MJ; Craig JI; MacEwan DJ; Rushworth SA; Bowles KM
Cell Cycle; 2015; 14(14):2367-75. PubMed ID: 25565020
[TBL] [Abstract][Full Text] [Related]
12. Methylsulfonylmethane Inhibits RANKL-Induced Osteoclastogenesis in BMMs by Suppressing NF-κB and STAT3 Activities.
Joung YH; Darvin P; Kang DY; Sp N; Byun HJ; Lee CH; Lee HK; Yang YM
PLoS One; 2016; 11(7):e0159891. PubMed ID: 27447722
[TBL] [Abstract][Full Text] [Related]
13. Interleukin-6 inhibits receptor activator of nuclear factor kappaB ligand-induced osteoclastogenesis by diverting cells into the macrophage lineage: key role of Serine727 phosphorylation of signal transducer and activator of transcription 3.
Duplomb L; Baud'huin M; Charrier C; Berreur M; Trichet V; Blanchard F; Heymann D
Endocrinology; 2008 Jul; 149(7):3688-97. PubMed ID: 18403479
[TBL] [Abstract][Full Text] [Related]
14. JNK/c-Jun signaling mediates an anti-apoptotic effect of RANKL in osteoclasts.
Ikeda F; Matsubara T; Tsurukai T; Hata K; Nishimura R; Yoneda T
J Bone Miner Res; 2008 Jun; 23(6):907-14. PubMed ID: 18251700
[TBL] [Abstract][Full Text] [Related]
15. A Novel Aziridine-based Bruton's Tyrosine Kinase Inhibitor Induces Apoptosis Through Down-regulation of p65/RelA Phosphorylation on Serine 536 and ERK1/2 in Mantle Cell Lymphoma.
Romanchikova N; Strods A; Strazdina J; Strumfs B; Trapencieris P
Anticancer Res; 2016 Nov; 36(11):6133-6140. PubMed ID: 27793942
[TBL] [Abstract][Full Text] [Related]
16. Bruton's tyrosine kinase prevents activation of the anti-apoptotic transcription factor STAT3 and promotes apoptosis in neoplastic B-cells and B-cell precursors exposed to oxidative stress.
Uckun F; Ozer Z; Vassilev A
Br J Haematol; 2007 Feb; 136(4):574-89. PubMed ID: 17367410
[TBL] [Abstract][Full Text] [Related]
17. Epidermal growth factor receptor regulates osteoclast differentiation and survival through cross-talking with RANK signaling.
Yi T; Lee HL; Cha JH; Ko SI; Kim HJ; Shin HI; Woo KM; Ryoo HM; Kim GS; Baek JH
J Cell Physiol; 2008 Nov; 217(2):409-22. PubMed ID: 18543257
[TBL] [Abstract][Full Text] [Related]
18. Gentiopicroside inhibits RANKL-induced osteoclastogenesis by regulating NF-κB and JNK signaling pathways.
Chen F; Xie L; Kang R; Deng R; Xi Z; Sun D; Zhu J; Wang L
Biomed Pharmacother; 2018 Apr; 100():142-146. PubMed ID: 29428661
[TBL] [Abstract][Full Text] [Related]
19. Honokiol potentiates apoptosis, suppresses osteoclastogenesis, and inhibits invasion through modulation of nuclear factor-kappaB activation pathway.
Ahn KS; Sethi G; Shishodia S; Sung B; Arbiser JL; Aggarwal BB
Mol Cancer Res; 2006 Sep; 4(9):621-33. PubMed ID: 16966432
[TBL] [Abstract][Full Text] [Related]
20. Caffeic acid phenethyl ester, an active component of honeybee propolis attenuates osteoclastogenesis and bone resorption via the suppression of RANKL-induced NF-kappaB and NFAT activity.
Ang ES; Pavlos NJ; Chai LY; Qi M; Cheng TS; Steer JH; Joyce DA; Zheng MH; Xu J
J Cell Physiol; 2009 Dec; 221(3):642-9. PubMed ID: 19681045
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
